Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.40, $0.03 better than the analyst estimate of $0.37. Revenue for the quarter came in at $3.08 billion versus the consensus estimate of $2.94 billion.

GUIDANCE:

Boston Scientific sees FY2021 EPS of $1.58-$1.62, versus the consensus of $1.58.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.